The 1st International Online Conference on Diseases



09-11 September 2025 | Online

Obesity in context: Challenging BMI and embracing metabolic diversity

P. Barciela¹, A. Perez-Vazquez¹, E. Yuksek¹, R. Nogueira-Marques¹, P. Donn¹, A. G. Pereira^{1,2}, M.A. Prieto^{1,*}

¹ Instituto de Agroecoloxía e Alimentación (IAA), Universidade de Vigo, Nutrition and Food Group (NuFoG), Campus Auga, 32004 Ourense, Spain.

² Investigaciones Agroalimentarias Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur). SERGAS-UVIGO.

1. INTRODUCTION & OBJECTIVES

The International Classification of Diseases first recorded obesity in 1948. The misconception that obesity is merely a lifestyle decision that can be reversible through the exercise of willpower has persisted in public discourse and in the medical community. Nevertheless, obesity is recognized by the World Health Organization (WHO) as a chronic disease characterized by "an abnormal or excessive accumulation of fat that is a health hazard". In the context of patient level care, there is a central and simple logical inconsistency: the therapeutic field is still based on the Body Mass Index (BMI; weight/height²). This marker is calculated using a BMI chart, which attempts to quantify a level of tissue mass (composed of bone, fat, and muscle) in an individual (Figure 1). This indicator, occasionally called the Quetelet index, only measures weight and height, without considering distribution of adiposity, muscle mass or metabolic impairments, leading to imprecise diagnoses. The consideration of obesity as a disease based on BMI alone impedes progress in social recognition and understanding of the disease, leading to unintended iatrogenesis and hindering research.

Hence, it is indispensable to better characterize body composition and metabolic status, as well as to differentiate between clinical and preclinical obesity, as a set of complex diseases, to target and treat more equitably.

The purpose of this systematic review is to address the latest progress in the ambiguity surrounding the diagnosis of obesity based on BMI and, how it impacts individuals.




Figure 1. Body mass index chat made in Excel.

2. WHY BMI IS INACCURATE AND MISLEADING?

- 1) It overlooks the physiological distinctions in body fat percentage among different genders (e.g., women have 10-13% essential body fat, while men have 2-5%).
- 2) Height biasing: BMI scales weight by height², rather than height³, leading to overestimation of height in tall subjects and underestimation in shorter ones.
- 3) Weight vs. fat: It cannot discriminate lean mass from fat mass or bone density, resulting in misclassifications of metabolic health as type I (false positives) or type II (false negatives) (Figure 2).

4) Athletic populations: large skeletal muscular mass raises BMI.




Figure 2. BMI categories, their association with body composition, and the potential health implications.

3. WHAT ARE ALTERNATIVE MEASURES TO BMI?

1) Adiposity measures:

- **Percentage body fat (PBF):** The ratio of fat to total body weight (%).
- **Skinfold thickness:** Subcutaneous body-fat measurement using skinfold calipers.
- **Bioelectrical impedance analysis (BIA):** A method that uses electrical current and resistance to measure body composition.
- **Dual-energy X-ray absorptiometry (DXA):** Medical imaging technique for bone mineral density (BMD) measurement using spectral imaging.

2) Fat distribution indicators:

- Waist circumference (WC)
- Waist-to-hip ratio (WHR)
- Waist-to-height ratio (WHtr)

3) Functional health indicators:

- VO₂ Max (maximum oxygen consumption)
- **Grip strength:** Overall health indicator that shows mobility, bone density, and heart health.
- Blood pressure, fasting glucose, lipid profile (cardiometabolic health panel)
 4) Composite index
 - Body adiposity index (BAI): hip circumference and height
 - Body Shape Index (ABSI): Height- and weight-adjusted waist circumference.

IS BMI A FAIR PROXY FOR OBESITY?

The conundrum of measuring BMI in large epidemiological samples has led to extensive research. Critics claim that BMI is insensitive to obesity and overlooks underlying metabolic disorders. Further, high BMI does not necessarily indicate disease. BMI fails to distinguish between fat and muscle, nor does it account for body composition. Thus, reliance on BMI can mislead research, public health policy, and societal perception. BMI is just one measure of obesity, and more advanced methods, like BAI, can provide a more accurate picture.

REFERENCES

Efremova, I., et al. (2023). Epidemiology of small intestinal bacterial overgrowth. World journal of gastroenterology, 29(22), 3400–3421. https://doi.org/10.3748/wjg.v29.i22.3400

Sachdev, A. H., & Pimentel, M. (2013). Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. *Therapeutic advances in chronic disease*, 4(5), 223–231. https://doi.org/10.1177/2040622313496126

Ghoshal, U. C., et al. (2017). Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy. Gut and liver, 11(2), 196–208. https://doi.org/10.5009/gnl16126

Wade W. (2002). Unculturable bacteria--the uncharacterized organisms that cause oral infections. *Journal of the Royal Society of*

Medicine, 95(2), 81–83. https://doi.org/10.1177/014107680209500207
Kashyap, P., et al. (2024). Critical appraisal of the SIBO hypothesis and breath testing: A clinical practice update endorsed by the European society of neurogastroenterology and motility (ESNM) and the American neurogastroenterology and motility, 36(6), e14817. https://doi.org/10.1111/nmo.14817

Velasco-Aburto, S., et al. (2025). Nutritional Approach to Small Intestinal Bacterial Overgrowth: A Narrative Review. *Nutrients*, 17(9), 1410. https://doi.org/10.3390/nu17091410

Gutin I. (2018). In BMI We Trust: Reframing the Body Mass Index as a Measure of Health. Social theory & health: STH, 16(3), 256–271. https://doi.org/10.1057/s41285-017-0055-0

ACKNOWLEDGMENTS

The research leading to these results was supported by Proyectos de Generación de Conocimiento 2023 (PID2023-148814OA-C22) supporting the predoctoral industrial grant for A. Perez-Vazquez (DIN2024-013416) in collaboration with Mercantia Desarrollos Alimentarios S.L; by Xunta de Galicia for supporting the pre-doctoral grant of P. Barciela (ED481A-2024-230). The authors also the EU-FORA Fellowship Program (EUBA-EFSA-2023-ENREL-01) that supports the work of F. Chamorro (INNOV2SAFETY-GA13) and S. Seyyedi-Mansour (ALGAESAFE-GA14).